Nippon India Pharma Fund vs Tata India Pharma & Healthcare Fund compare
Nippon India Pharma Fund-Growth Plan-Growth Option
Tata India Pharma & Healthcare Fund-Regular Plan-Growth
Chart Comparison
Overview
Scheme Name | Nippon India Pharma Fund-Growth Plan-Growth Option | Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
---|---|---|
Fund | Nippon India Pharma Fund-Growth Plan-Growth Option | Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
Investment Plan | Growth | Growth |
Level of Risk | Very High Risk | Very High |
Asset Size (Cr) | ₹8161 Cr | ₹1208 Cr |
Min Investment | ₹5000 | ₹5000 |
Min SIP Invesment | ₹500 | ₹100 |
Min Addl Investment | ₹1000 | ₹1000 |
Launch Date | 05 Jun 2004 | 28 Dec 2015 |
Category | Pharma & Healthcare | Pharma & Healthcare |
Fund Type | Open Ended | Open Ended |
Benchmark | BSE Healthcare | Nifty Pharma TRI |
Turn Over | 21% | 26.49% |
Expense Ratio | 1.82 | 2.14 |
Manager | Sailesh Raj Bhan | Meeta Shetty |
ISIN Code | INF204K01968 | INF277K016A9 |
Exits Load | Nippon India Pharma Fund - Growth charges 1.0% of sell value; if fund sold before 30 days. There are no other charges./365 | Tata India Pharma & Heathcare Fund - Growth charges 0.25% of sell value; if fund sold before 30 days. There are no other charges./365 |
Trailing Lumpsum Returns
Scheme Name | Nippon India Pharma Fund-Growth Plan-Growth Option | Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
---|---|---|
1 Month | -6% | -7.82% |
6 Month | -8.47% | -8.67% |
1 Year | 6.77% | 8.93% |
3 Year | 18.71% | 18.99% |
5 Year | 22.93% | 22.08% |
SIP Return Analysis
Scheme Name | Nippon India Pharma Fund-Growth Plan-Growth Option | Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
---|---|---|
6 Month | - | - |
1 Year | -2.3% | -1.69% |
3 Year | 21.23% | 21.97% |
5 Year | 19.2% | 19.47% |
Rolling Lumpsum Returns
Scheme Name | Nippon India Pharma Fund-Growth Plan-Growth Option | Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
---|---|---|
1 Year | 18.19% | 7.82% |
3 Year | 20.5% | 17.79% |
5 Year | 20.36% | 14.55% |
Risk Management
Scheme Name | Nippon India Pharma Fund-Growth Plan-Growth Option | Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
---|---|---|
Standard Deviation | 15.185% | 15.471% |
Sharp | 0.81% | 0.874% |
Beta | 0.931% | 0.953% |
Alpha | -0.33% | 0.602% |
Still Confused Which Fund To Select? Don’t worry! We’re just a call away.
Get Free Experts Guidance
Fund Managers
Scheme Name | Nippon India Pharma Fund-Growth Plan-Growth Option | Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
---|---|---|
Name | Sailesh Raj Bhan | Meeta Shetty |
Total AUM | ₹96086 Cr | ₹17847 Cr |
Fund Manage | 5 | 5 |
Nippon India Pharma Fund-Growth Plan-Growth Option | Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
Market Cap
Scheme Name |
Nippon India Pharma Fund-Growth Plan-Growth Option |
Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
---|---|---|
Others | 4.4 | 5.39 |
Large Cap | 45.96 | 40.33 |
Mid Cap | 27.12 | 30.82 |
Small Cap | 22.52 | 23.46 |
Sector Allocation
Scheme Name |
Nippon India Pharma Fund-Growth Plan-Growth Option |
Tata India Pharma & Healthcare Fund-Regular Plan-Growth |
---|---|---|
Others | 4.4 | 5.39 |
Pharmaceuticals & Biotechnology | 75.86 | 76.28 |
Healthcare Services | 17.38 | 14.31 |
Retailing | 2.36 | 0.66 |
Fertilizers & Agrochemicals | - | 0.83 |
Chemicals & Petrochemicals | - | 0.39 |
Insurance | - | 2.14 |
Top Comparisons
Motilal Oswal Nifty Midcap 150 Index Fund - Regular Plan
3Y Returns19.73%
IDBI Nifty Next 50 Index Fund Growth
3Y Returns14.38%
HDFC Focused 30 Fund - GROWTH PLAN
3Y Returns22.48%
SBI Focused Equity Fund - Regular Plan -Growth
3Y Returns10.94%
SBI Multi Asset Allocation Fund - Regular Plan - Growth
3Y Returns13.69%
Edelweiss Multi Asset Allocation Fund - Reg (G)
3Y Returns0%
DSP World Mining Fund - Regular Plan - Growth
3Y Returns1.07%
Edelweiss US Technology Equity Fund of Fund- Regular Plan- Growth
3Y Returns20.6%